Study ID	Study follow‐up (months)	CoronaVac (n)	Placebo (n)	Critical outcomes
				Confirmed SARS‐CoV‐2 infection after complete vaccination	Confirmed symptomatic COVID‐19 after complete vaccination	Severe or critical COVID‐19	All‐cause mortality	Systemic reactogenicity events	Any AE	SAE
Zhang 2021 (NCT04352608) Phase 2	1.41	120	60	*	*	*	*	✓	✓	X
Zhang 2021 (NCT04352608) Phase 1	1.41	24	24	*	*	*	*	✓	✓	✓
Bueno 2021a (NCT04651790)	1.4	270	164	*	*	*	*	✓	*	✓
Han 2021 (NCT04551547)	4.1	219	114	*	*	*	*	*	✓	✓
Palacios 2020 (NCT04456595)	12	6201	6207	*	✓	✓	✓	✓	✓	✓
Tanriover 2021 (NCT04582344)	6	6650	3568	X	✓	✓	✓	✓	✓	✓
Wu 2021a (NCT04383574)	1.84	124	74	*	*	*	*	✓	✓	✓
Li 2021aa (NCT04383574)	10.46	100	50	*	*	*	*	✓	✓	✓
Pan 2021ab (NCT04352608)		60	30	*	*	*	*	✓	✓	✓